Radiofrequency ablation for hepatocellular carcinoma: Updated review in 2010

Oncology

Volumn 78, Issue SUPPL. 1, 2010, Pages 113-124

  Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Radiofrequency ablation; RFA, complications; RFA, outcomes; Treatment algorithm

Indexed keywords

INTERFERON; PERFLUBUTANE; SONOVUE;

ASCITES; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; ECHOGRAPHY; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER RESECTION; MOLECULAR THERAPY; PLEURA EFFUSION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; HUMANS; LIVER NEOPLASMS; TREATMENT OUTCOME;

EID: 77954498329     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315239     Document Type: Review

References (92)

1. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC: Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 1151-1156.
2. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T, et al: A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-130.
3. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M: Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009; 104: 514-524.
4. Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, Sacchetto P, Gandini G, Rizzetto M: Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008; 43: 727-735.
5. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M, et al: Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38: 37-51.
6. The Japan Society of Hepatology: Evidence- Based Clinical Practice Guideline for Hepatocellular Carcinoma (revised version) (in Japanese). Tokyo, Kanehara, 2009.
7. The Japan Society of Hepatology: Consensus- Based Clinical Practice Manual. Tokyo, Igakushoin, 2007.
8. Kudo M, Okanoue T: Management of hepatocellular carcinoma in Japan: consensusbased clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007; 72(suppl):2-15.
9. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
10. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, et al: Report of the 17th Nationwide Follow-Up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37: 676-691.
11. Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, Okita K, Omata M, Kudo M, Kojiro M, et al: Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol 2008; 49: 589-594.
12. Ogihara M, Wong LL, Machi J: Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes. HPB (Oxford) 2005; 7: 214-221.
13. Lupo L, Panzera P, Giannelli G, Memeo M, Gentile A, Memeo V: Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection? HPB (Oxford) 2007; 9: 429-434.
14. Ueno S, Sakoda M, Kubo F, Hiwatashi K, Tateno T, Baba Y, Hasegawa S, Tsubouchi H: Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan Criteria. J Hepatobiliary Pancreat Surg 2009; 16: 359-366.
15. Molinari M, Helton S: Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis. Am J Surg 2009; 198: 396-406.
16. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S: Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008; 47: 82-89.
17. Guglielmi A, Ruzzenente A, Valdegamberi A, Pachera S, Campagnaro T, D'Onofrio M, Martone E, Nicoli P, Iacono C: Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2008; 12: 192-198.
18. Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A: Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 2004; 240: 102-107.
19. Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Nagai T, Minami Y, et al: PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy. Oncology 2008; 75(suppl 1): 91-98.
20. Chen MH, Yang W, Yan K, Hou YB, Dai Y, Gao W, Zhang H, Wu W: Radiofrequency ablation of problematically located hepatocellular carcinoma: tailored approach. Abdom Imaging 2008; 33: 428-436. (Pubitemid 351713079)
21. Takaki H, Yamakado K, Uraki J, Nakatsuka A, Fuke H, Yamamoto N, Shiraki K, Yamada T, Takeda K: Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm. J Vasc Interv Radiol 2009; 20: 217-224.
22. Kirikoshi H, Saito S, Yoneda M, Fujita K, Mawatari H, Uchiyama T, Higurashi T, Goto A, Takahashi H, Abe Y, et al: Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. Hepatol Res 2009; 39: 553-562.
23. Peng ZW, Chen MS, Liang HH, Gao HJ, Zhang YJ, Li JQ, Zhang YQ, Lau WY: A casecontrol study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol 2010; 36: 257-263.
24. Yamakado K, Nakatsuka A, Takaki H, Yokoi H, Usui M, Sakurai H, Isaji S, Shiraki K, Fuke H, Uemoto S, et al: Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology 2008; 247: 260-266.
25. Lee MW, Kim YJ, Park SW, Jeon HJ, Yi JG, Choe WH, Kwon SY, Lee CH: Percutaneous radiofrequency ablation of liver dome hepatocellular carcinoma invisible on ultrasonography: a new targeting strategy. Br J Radiol 2008; 81:e130-e134.
26. Kitamoto M, Imagawa M, Yamada H, Watanabe C, Sumioka M, Satoh O, Shimamoto M, Kodama M, Kimura S, Kishimoto K, et al: Radiofrequency ablation in the treatment of small hepatocellular carcinomas: compari son of the radiofrequency effect with and without chemoembolization. AJR Am J Roentgenol 2003; 181: 997-1003.
27. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, et al: Management of Hepatocellular Carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology 2009. Hepatol Res 2010, in press.
28. Kudo M: Local ablation therapy for hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2004; 39: 205-214.
29. Rhim H, Lim HK, Kim YS, Choi D: Percutaneous radiofrequency ablation with artificial ascites for hepatocellular carcinoma in the hepatic dome: initial experience. AJR Am J Roentgenol 2008; 190: 91-98.
30. Minami Y, Kudo M, Kawasaki T, Chung H, Ogawa C, Shiozaki H: Percutaneous radiofrequency ablation guided by contrast-enhanced harmonic sonography with artificial pleural effusion for hepatocellular carcinoma in the hepatic dome. AJR Am J Roentgenol 2004; 182: 1224-1226.
31. Wang ZY, Sun WB, Li MY, Zhang XX, Ding XM: Percutaneous extrapulmonary radiofrequency ablation for tumors in the hepatic dome. Hepatogastroenterology 2008; 55: 1164-1166.
32. Kondo Y, Yoshida H, Tateishi R, Shiina S, Kawabe T, Omata M: Percutaneous radiofrequency ablation of liver cancer in the hepatic dome using the intrapleural fluid infusion technique. Br J Surg 2008; 95: 996-1004.
33. Park BJ, Byun JH, Jin YH, Won HJ, Shin YM, Kim KW, Park SJ, Kim PN: CT-guided radiofrequency ablation for hepatocellular carcinomas that were undetectable at US: therapeutic effectiveness and safety. J Vasc Interv Radiol 2009; 20: 490-499.
34. Nakai M, Sato M, Sahara S, Takasaka I, Kawai N, Minamiguchi H, Tanihata H, Kimura M, Takeuchi N: Radiofrequency ablation assisted by real-time virtual sonography and CT for hepatocellular carcinoma undetectable by conventional sonography. Cardiovasc Intervent Radiol 2009; 32: 62-69.
35. Minami Y, Chung H, Kudo M, Kitai S, Takahashi S, Inoue T, Ueshima K, Shiozaki H: Radiofrequency ablation of hepatocellular carcinoma: value of virtual CT sonography with magnetic navigation. AJR Am J Roentgenol 2008; 190:W335-W341.
36. Minami Y, Kudo M, Chung H, Inoue T, Takahashi S, Hatanaka K, Ueda T, Hagiwara H, Kitai S, Ueshima K, et al: Percutaneous radiofrequency ablation of sonographically unidentifiable liver tumors. Feasibility and usefulness of a novel guiding technique with an integrated system of computed tomography and sonographic images. Oncology 2007; 72(suppl 1):111-116.
37. Kawasoe H, Eguchi Y, Mizuta T, Yasutake T, Ozaki I, Shimonishi T, Miyazaki K, Tamai T, Kato A, Kudo S, et al: Radiofrequency ablation with the real-time virtual sonography system for treating hepatocellular carcinoma difficult to detect by ultrasonography. J Clin Biochem Nutr 2007; 40: 66-72.
38. Kudo M, Hatanaka K, Maekawa K: Sonazoid- enhanced ultrasound in the diagnosis and treatment of hepatic tumors. J Med Ultrasound 2008; 16: 130-139.
39. Kudo M, Hatanaka K, Maekawa K: Defect reperfusion imaging, a newly developed novel technology using Sonazoid in the treatment of hepatocellular carcinoma. J Med Ultrasound 2008; 16: 169-175.
40. Kudo M, Hatanaka K, Chung H, Minami Y, Maekawa K: A proposal of novel treatmentassist technique for hepatocellular carcinoma in the Sonazoid-enhanced ultrasonography: value of defect re-perfusion imaging (in Japanese). Kanzo 2007; 48: 299-301
41. Minami Y, Kudo M, Chung H, Kawasaki T, Yagyu Y, Shimono T, Shiozaki H: Contrast harmonic sonography-guided radiofrequency ablation therapy versus B-mode sonography in hepatocellular carcinoma: prospective randomized controlled trial. AJR Am J Roentgenol 2007; 188: 489-494.
42. Maruyama H, Takahashi M, Ishibashi H, Okugawa H, Okabe S, Yoshikawa M, Yokosuka O: Ultrasound-guided treatments under low acoustic power contrast harmonic imaging for hepatocellular carcinomas undetected by B-mode ultrasonography. Liver Int 2009; 29: 708-714.
43. Miyamoto N, Hiramatsu K, Tsuchiya K, Sato Y, Terae S, Shirato H: Sonazoid-enhanced sonography for guiding radiofrequency ablation for hepatocellular carcinoma: better tumor visualization by Kupffer-phase imaging and vascular-phase imaging after reinjection. Jpn J Radiol 2009; 27: 185-193.
44. Minami Y, Kudo M, Kawasaki T, Chung H, Ogawa C, Shiozaki H: Treatment of hepatocellular carcinoma with percutaneous radiofrequency ablation: usefulness of contrast harmonic sonography for lesions poorly defined with B-mode sonography. AJR Am J Roentgenol 2004; 183: 153-156.
45. Miyamoto N, Hiramatsu K, Tsuchiya K, Sato Y: Carbon dioxide microbubbles-enhanced sonographically guided radiofrequency ablation: treatment of patients with local progression of hepatocellular carcinoma. Radiat Med 2008; 26: 92-97.
46. Choi D, Lim HK, Kim MJ, Kim SH, Lee WJ, Lim JH, Paik SW, Koh KC, Yoo BC: Therapeutic efficacy and safety of percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the gastrointestinal tract. AJR Am J Roentgenol 2004; 183: 1417-1424.
47. Park SY, Tak WY, Jeon SW, Cho CM, Kweon YO, Kim SK, Choi YH: The efficacy of intraperitoneal saline infusion for percutaneous radiofrequency ablation for hepatocellular carcinoma. Eur J Radiol 2010;74:536-540.
48. Song I, Rhim H, Lim HK, Kim YS, Choi D: Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients. Eur Radiol 2009.
49. Lam VW, Ng KK, Chok KS, Cheung TT, Wat J, Fan ST, Poon RT: Safety and efficacy of radiofrequency ablation for periductal hepatocellular carcinoma with intraductal cooling of the central bile duct. J Am Coll Surg 2008; 207:e1-e5.
50. Ohnishi T, Yasuda I, Nishigaki Y, Hayashi H, Otsuji K, Mukai T, Enya M, Omar S, Soehendra N, Tomita E, et al: Intraductal chilled saline perfusion to prevent bile duct injury during percutaneous radiofrequency ablation for hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23:e410-e415.
51. Mulier S, Mulier P, Ni Y, Miao Y, Dupas B, Marchal G, De Wever I, Michel L: Complications of radiofrequency coagulation of liver tumours. Br J Surg 2002; 89: 1206-1222.
52. Peng ZW, Liang HH, Chen MS, Zhang YJ, Li JQ, Zhang YQ, Lau WY: Percutaneous radiofrequency ablation for the treatment of hepatocellular carcinoma in the caudate lobe. Eur J Surg Oncol 2008; 34: 166-172.
53. Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I, Furuse J, Nakamura K, Makuuchi M, et al: Response evaluation criteria in cancer of the liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2010 Revised Version). Hepatol Res 2010, in press.
54. Nakashima Y, Nakashima O, Tanaka M, Okuda K, Nakashima M, Kojiro M: Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res 2003; 26: 142-147.
55. Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Fukushima N, Sakamoto M: Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 2002; 95: 1931-1937.
56. Zytoon AA, Ishii H, Murakami K, El-Kholy MR, Furuse J, El-Dorry A, El-Malah A: Recurrence- free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome. Jpn J Clin Oncol 2007; 37: 658-672.
57. Nishijima N, Osaki Y, Kita R, Eso Y, Yamanaka S, Kawakami H, et al: Proposal of the radicality grading as a criterion for therapeutic effectiveness of RFA against hepatocellular carcinoma, in relation to the local recurrence rate (in Japanese). Acta Hepatol Jpn 2008; 49: 192-199.
58. Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Minami Y, Ueshima K, et al: Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology 2007; 72(suppl 1):98-103.
59. Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, Ayuso C, Bru C, Bruix J: Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40: 1352-1360.
60. Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST: Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg 2008; 12: 183-191.
61. Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, Tso WK, Fan ST, Poon RT: Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 2008; 207: 20-29.
62. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, Frings H, Laubenberger J, Zuber I, Blum HE, et al: Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-240.
63. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC: Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ! or = 4 cm. Gastroenterology 2004; 127: 1714-1723.
64. Wen YL, Kudo M, Zheng RQ, Minami Y, Chung H, Suetomi Y, Onda H, Kitano M, Kawasaki T, Maekawa K: Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography. AJR Am J Roentgenol 2003; 181: 57-63.
65. Bartolotta TV, Taibbi A, Midiri M, De Maria M: Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound. Abdom Imaging 2008; 33: 501-511.
66. Zhou P, Kudo M, Minami Y, Chung H, Inoue T, Fukunaga T, Maekawa K: What is the best time to evaluate treatment response after radiofrequency ablation of hepatocellular carcinoma using contrast-enhanced sonography? Oncology 2007; 72(suppl 1):92-97.
67. Mori K, Fukuda K, Asaoka H, Ueda T, Kunimatsu A, Okamoto Y, Nasu K, Fukunaga K, Morishita Y, Minami M: Radiofrequency ablation of the liver: determination of ablative margin at MR imaging with impaired clearance of ferucarbotran - feasibility study. Radiology 2009; 251: 557-565.
68. De Baere T, Risse O, Kuoch V, Dromain C, Sengel C, Smayra T, Gamal El Din M, Letoublon C, Elias D: Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol 2003; 181: 695-700.
69. Goldberg SN, Charboneau JW, Dodd GD 3rd, Dupuy DE, Gervais DA, Gillams AR, Kane RA, Lee FT Jr, Livraghi T, McGahan JP, et al: Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology 2003; 228: 335-345.
70. Chen TM, Huang PT, Lin LF, Tung JN: Major complications of ultrasound-guided percutaneous radiofrequency ablations for liver malignancies: single center experience. J Gastroenterol Hepatol 2008; 23:e445-e450.
71. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN: Treatment of focal liver tumors with percutaneous radiofrequency ablation: complications encountered in a multicenter study. Radiology 2003; 226: 441-451.
72. Curley SA, Marra P, Beaty K, Ellis LM, Vauthey JN, Abdalla EK, Scaife C, Raut C, Wolff R, Choi H, et al: Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 2004; 239: 450-458.
73. Kasugai H, Osaki Y, Oka H, Kudo M, Seki T: Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients. Oncology 2007; 72(suppl 1):72-75.
74. Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK: Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007; 33: 437-447.
75. Latteri F, Sandonato L, Di Marco V, Parisi P, Cabibbo G, Lombardo G, Galia M, Midiri M, Latteri MA, Craxi A: Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. Dig Liver Dis 2008; 40: 684-689.
76. Imamura J, Tateishi R, Shiina S, Goto E, Sato T, Ohki T, Masuzaki R, Goto T, Yoshida H, Kanai F, et al: Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol 2008; 103: 3057-3062.
77. Perkins JD: Seeding risk following percutaneous approach to hepatocellular carcinoma. Liver Transpl 2007; 13: 1603.
78. Kong WT, Zhang WW, Qiu YD, Zhou T, Qiu JL, Zhang W, Ding YT: Major complications after radiofrequency ablation for liver tumors: analysis of 255 patients. World J Gastroenterol 2009; 15: 2651-2656.
79. Llovet JM, Vilana R, Bru C, Bianchi L, Salmeron JM, Boix L, Ganau S, Sala M, Pages M, Ayuso C, et al: Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001; 33: 1124-1129.
80. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P: Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000; 232: 381-391.
81. De Baere T, Roche A, Amenabar JM, Lagrange C, Ducreux M, Rougier P, Elias D, Lasser P, Patriarche C: Liver abscess formation after local treatment of liver tumors. Hepatology 1996; 23: 1436-1440.
82. Chopra S, Dodd GD 3rd, Chanin MP, Chintapalli KN: Radiofrequency ablation of hepatic tumors adjacent to the gallbladder: feasibility and safety. AJR Am J Roentgenol 2003; 180: 697-701.
83. Giorgio A, Tarantino L, de Stefano G, Coppola C, Ferraioli G: Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a single center. AJR Am J Roentgenol 2005; 184: 207-211.
84. Seki T, Tamai T, Ikeda K, Imamura M, Nishimura A, Yamashiki N, Nakagawa T, Inoue K: Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur J Gastroenterol Hepatol 2001; 13: 291-294.
85. Koda M, Maeda Y, Matsunaga Y, Mimura K, Murawaki Y, Horie Y: Hepatocellular carcinoma with sarcomatous change arising after radiofrequency ablation for well-differentiated hepatocellular carcinoma. Hepatol Res 2003; 27: 163-167.
86. Portolani N, Tiberio GA, Ronconi M, Coniglio A, Ghidoni S, Gaverini G, Giulini SM: Aggressive recurrence after radiofrequency ablation of liver neoplasms. Hepatogastroenterology 2003; 50: 2179-2184.
87. Takada Y, Kurata M, Ohkohchi N: Rapid and aggressive recurrence accompanied by portal tumor thrombus after radiofrequency ablation for hepatocellular carcinoma. Int J Clin Oncol 2003; 8: 332-335.
88. Ruzzenente A, Manzoni GD, Molfetta M, Pachera S, Genco B, Donataccio M, Guglielmi A: Rapid progression of hepatocellular carcinoma after radiofrequency ablation. World J Gastroenterol 2004; 10: 1137-1140.
89. Kudo M, Sakaguchi Y, Chung H, Hatanaka K, Hagiwara S, Ishikawa E, Takahashi S, Kitai S, Inoue T, Minami Y, et al: Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology 2007; 72(suppl):132-138.
90. Kudo M: Impact of interferon therapy after curative treatment of hepatocellular carcinoma. Oncology 2008; 75(suppl 1):30-41.
91. Ishikawa T: Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J Gastroenterol 2008; 14: 6140-6144.
92. Lencioni R, Crocetti L, Petruzzi P, Vignali C, Bozzi E, Della Pina C, Bargellini I, Cioni D, Oliveri F, De Simone P, et al: Doxorubicineluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol 2008; 49: 217-222.